Arena Pharmaceuticals, Inc. news

   Watch this stock
Showing stories 1 - 10 of about 89   

Articles published

ARNA 1.68 -0.10 (-5.62%)
price chart
Stock Displaying Signs of a Downtrend: Arena Pharmaceuticals, Inc. (NASDAQ:ARNA)
Shares of Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) have been on a consistent downtrend as of late, causing concern for stock owners.
Arena Pharma stock rises 8.8% after weight-loss drug is approved
Arena Pharmaceuticals Inc. ARNA, -5.62% shares rose 8.8% in pre-market trade Tuesday after the company said its weight-loss drug with Eisai Inc. 4523, +0.46% received Food and Drug Administration approval.
Arena Pharmaceuticals Inc Stock Technicals at Critical Inflection Point
This is a technical analysis stock rating for Arena Pharmaceuticals Inc (NASDAQ:ARNA) . The company has a three bull technical rating which indicates an inflection point.
How Analysts Feel About Arena Pharmaceuticals, Inc. (NASDAQ:ARNA)?
Out of 2 analysts covering Arena Pharmaceuticals (NASDAQ:ARNA), 1 rate it a “Buy”, 0 “Sell”, while 1 “Hold”.
Eisai Inc. and Arena Pharmaceuticals Announce FDA Approval of BELVIQ XR ...
WOODCLIFF LAKE, N.J. and SAN DIEGO, July 19, 2016 /PRNewswire/ -- Eisai Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that the U.S.
What Arena's Recent FDA Approval Means For The Future  Seeking Alpha
Company Update (NASDAQ:ARNA): Arena Pharmaceuticals, Inc. and Eisai Inc ...
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) and Eisai Inc. announced that the Federal Commission for the Protection Against Sanitary Risk (COFEPRIS) has granted regulatory approval of the chronic weight management agent VENESPRI´┐Ż(lorcaserin HCl: ...
Arena Pharmaceuticals Inc. (NASDAQ:ARNA) Receives Consensus Rating of " ...  BBNS
Arena Pharmaceuticals boosted as obesity drug gets Mexican approval  Proactive Investors USA & Canada
Two Stocks to Watch: OpGen, Inc. (NASDAQ:OPGN) , Arena Pharmaceuticals, Inc ...
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) showed move of +0.00% after exchanging volume of 1.16 million shares in last trading session ended on 7/21/2016.
Trading the Biotech News: Celgene Corporation (NASDAQ:CELG), Arena ...
Celgene Corporation (NASDAQ:CELG) lost -0.43% by the end of recent close at $102.26. For the ongoing quarter, the 25 Wall Street analysts providing adjusted earnings per share outlook have a consensus estimate of $1.37/share, which would compare ...
Stock Performance to Track: Arena Pharmaceuticals, Inc. (NASDAQ:ARNA)
The Company gained 3.49% and finished at $1.78. The daily volume was measured at 1.2 million shares. The 52-week high of the share price is $4.31 and the 52-week low is $1.3.
Biotech Stocks Worth Chasing: Arena Pharmaceuticals, Inc. (ARNA), ZIOPHARM ...
Arena Pharmaceuticals, Inc. (ARNA) ended last trading session with a change of 2.41 percent. It trades at an average volume of 1.75M shares versus 1.84M shares recorded at the end of last trading session.